Vanderbilt Center for Antibody Therapeutics (VCAT)

February 20, 2026

Ancient teeth, enduring patterns: Mummy study supports oral-cardiovascular disease link

CT scans of 37 Egyptian mummies and found strong correlations between oral disease and calcified blood vessels, offering new evidence that the link between dental and cardiovascular health spans 4,000 years of human history.

By Bill Snyder
(iStock)
February 13, 2026

Anti-Marburg antibody from Vanderbilt Health sent to Ethiopia during outbreak

There currently are no approved treatments or vaccines to protect against the infection, which can cause internal bleeding, organ failure, and in roughly 50% of cases, death.

By Bill Snyder
December 15, 2025

Antibody research may lead to broadly protective flu vaccine

These findings could lead to the development of cross-reactive and neutralizing antibody therapies for individuals who are severely ill from the flu.

By Bill Snyder
November 17, 2025

VUMC’s Robert Carnahan named a 2025 Master Innovator

He is a translational scientist and antibody engineer who specializes in rapid therapeutic development for emerging infectious diseases.

(iStock)
July 8, 2025

Vanderbilt, Parse Biosciences scientists envision an antibody ‘atlas’ for measles, mumps, rubella

Researchers will scan the landscape of plasmablasts, the first antibody-producing, B-type immune cells that respond to MMR infection.

By Bill Snyder
December 11, 2024

Vanderbilt joins national effort to develop alphavirus vaccines

The project aims to design computational “tool kits” that can speed development of multi-virus vaccines targeting some of the greatest infectious threats to human health.

By Bill Snyder and Herschel Pollard
November 4, 2024

James Crowe Jr. honored for his innovative research on human antibodies

Crowe and his colleagues have developed cutting-edge technologies to isolate and study antiviral antibodies.
By Bill Snyder
October 28, 2024

VUMC discovery aids effort to stop a deadly virus in Rwanda

A close cousin of Ebola, the Marburg virus is transmitted by fruit bats and by exposure to body fluids from infected individuals. There currently are no approved treatments or vaccines for MVD, which has a roughly 50% fatality rate.
By Bill Snyder
September 20, 2024

VUMC method tracks down rare, broadly reacting antibodies: study

The discovery, reported in the journal PLOS Pathogens, could help open the door to the development of effective vaccines and antibody therapies with an “exceptional breadth of pathogen coverage.”
By Bill Snyder
September 13, 2024

VUMC joins national effort to prevent another pandemic

Developed in the wake of the COVID-19 pandemic, ReVAMPP will support a coordinating center and seven research centers, including VUMC, with a focus on nine virus groups that pose the greatest risk to human health.
By Bill Snyder
August 13, 2024

VUMC, DOD join forces for a hantavirus antibody “sprint”

VUMC’s antibody collaboration with the DOD goes back to 2018, when the medical center signed a five-year cooperative agreement with the U.S. Defense Advanced Research Projects Agency to develop protective treatments that can be rushed to health care providers within weeks after a viral outbreak.
By Bill Snyder
June 28, 2024

Antibody trial launched to address enterovirus threat

Enterovirus D68 has caused an increasing number of infections during the past decade and is associated with acute flaccid myelitis, a polio-like condition that mostly affects children and causes sudden weakness and paralysis.
By Bill Snyder
June 12, 2024

Scientists find antibodies that block parainfluenza virus infection

The antibodies may have clinical benefit as antiviral drugs to treat potentially life-threatening infections in elderly and immunosuppressed patients.
By Bill Snyder